Year: 2025
Type: article
Abstract: Beyond the 177Lu-based radiopharmaceuticals targeting somatostatin receptor and prostate-specific membrane antigen, there are new therapeutic radiopharmaceuticals that can potentially reach the market within the next 10 y. These molecules are labeled with 67Cu, 90Y, 131I, 161Tb, 188Re, 211At, 212Pb
Source: Journal of Nuclear Medicine
Author: Richard Zimmermann
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4408947240